Top Story
Patient Outcomes & EngagementTakeda's Entyvio, a medication for Crohn's disease, has been approved for a subcutaneous (SC) formulation. Originally an intravenous (IV) infusion drug from 2014, this new option allows patients to self-administer the treatment with a prefilled pen, offering convenience and flexibility for at-home use. Takeda announced this [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/22/2024 04:44 PM ET
ASLAN Pharmaceuticals Limited ASLN date announcement
ASLAN Pharmaceuticals Limited now has four catalyst announcements on the calendar after revealing the date on which they will release trial results for Eblasakimab (ASLAN004) - (TREK-DX). Now that the Phase 2b trial is completed, [...]
Read More
04/19/2024 04:43 PM ET
YS Biopharma Co. Ltd. YS earnings announcement
YS Biopharma Co. Ltd. fell in line with their revenue estimate but fell short of their EPS estimate, according to their recent quarterly earnings data. EPS was -$0.12, missing estimates by [...]
Read More
04/18/2024 04:44 PM ET
Vertex Pharmaceuticals Incorporated VRTX date announcement
Vertex Pharmaceuticals Incorporated, makers of Suzetrigine (VX-548), will be announcing their top-line results for the drug's recent NDA Filing trial on August 31, 2024. Our calculations show a 70.7% chance that the drug makes [...]
Read More
04/18/2024 04:44 PM ET
Immutep Limited IMMP results announcement
Immutep Limited released new information about their Phase 1 trial for IMP761. Our analysts provided the following summary:
"Trial planned for mid-2024."
This is one of three upcoming announcements for the company.
The market was [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
